BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hashimoto Y, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saito S, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H. Clinical and virological effects of long-term (over 5 years) lamivudine therapy: Five-Year Lamivudine Therapy for Chronic HBV Infection. J Med Virol 2010;82:684-91. [DOI: 10.1002/jmv.21681] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Kamezaki H, Kanda T, Arai M, Wu S, Nakamoto S, Chiba T, Maruyama H, Fujiwara K, Kanai F, Imazeki F. Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine. Int J Med Sci. 2013;10:567-574. [PMID: 23533048 DOI: 10.7150/ijms.5795] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
2 Kusumoto S, Tobinai K. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. Hematology Am Soc Hematol Educ Program. 2014;2014:576-583. [PMID: 25696914 DOI: 10.1182/asheducation-2014.1.576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
3 Liu H, Wan Z, She L, Zhu Y, Cai Z, Wu B, Zhuang Q, Ke P, Wu X, Li Z, Huang X. Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus. Front Pharmacol 2021;12:648170. [PMID: 33935748 DOI: 10.3389/fphar.2021.648170] [Reference Citation Analysis]
4 Huang YJ, Yang SS, Yeh HZ, Chang CS, Peng YC. Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B. PLoS One 2019;14:e0221958. [PMID: 31469875 DOI: 10.1371/journal.pone.0221958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Wei L, Kao JH. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Curr Med Res Opin 2017;33:495-504. [PMID: 27882776 DOI: 10.1080/03007995.2016.1264932] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
6 Suzuki F, Suzuki Y, Hosaka T, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol 2017;52:641-51. [PMID: 27699721 DOI: 10.1007/s00535-016-1270-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
7 Kwon JH, Jang JW, Choi JY, Park CH, Yoo SH, Bae SH, Yoon SK. Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment? J Med Virol. 2013;85:34-42. [PMID: 23154874 DOI: 10.1002/jmv.23421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
8 Fasano M, Lampertico P, Marzano A, Di Marco V, Niro GA, Brancaccio G, Marengo A, Scotto G, Brunetto MR, Gaeta GB, Rizzetto M, Angarano G, Santantonio T. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 2012;56:1254-8. [PMID: 22343167 DOI: 10.1016/j.jhep.2012.01.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
9 Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1-58. [PMID: 24397839 DOI: 10.1111/hepr.12269] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 14.7] [Reference Citation Analysis]
10 Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, Hotta M, Yoshimura H, Ishii K, Ito T, Nomura S. Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA? Leuk Res 2016;50:46-9. [PMID: 27665181 DOI: 10.1016/j.leukres.2016.09.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
11 Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88:6805-6818. [PMID: 24696492 DOI: 10.1128/jvi.00635-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
12 Shi TD, Zhang JM, Wang XF, Chen M, Sun H, Chen CB, Ren H. Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clin Exp Med. 2012;12:105-113. [PMID: 21748522 DOI: 10.1007/s10238-011-0151-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
13 Hu TH, Tsai MC, Chen YT, Chien YS, Hung CH, Chen TC, Tseng PL, Chang KC, Yen YH. The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up. Hepatol Int. 2011;16. [PMID: 21744310 DOI: 10.1007/s12072-011-9295-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol. 2014;49:470-480. [PMID: 23525978 DOI: 10.1007/s00535-013-0779-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
15 Tadokoro K, Suzuki F, Kobayashi M, Yamaguchi T, Nagano M, Egashira T, Kumada H. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay. J Virol Methods. 2011;171:67-73. [PMID: 20950650 DOI: 10.1016/j.jviromet.2010.10.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
16 Ma YX, Song ZW, Teng X, Fu LJ, Hao ML, Chen SJ, Xu WZ, Gu HX. Successful establishment and evaluation of a new animal model for studying the hepatitis B virus YVDD mutant. Arch Virol 2013;158:785-91. [PMID: 23183771 DOI: 10.1007/s00705-012-1550-1] [Reference Citation Analysis]
17 Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol 2011; 17(24): 2945-2952 [PMID: 21734806 DOI: 10.3748/wjg.v17.i24.2945] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]